RedHill Biopharma (RDHL) Shares Outstanding (2017 - 2025)

RedHill Biopharma (RDHL) has 9 years of Shares Outstanding data on file, last reported at $50.9 billion in Q4 2025.

• Shares Outstanding for Q4 2025 came in at $50.9 billion, up 294.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $50.9 billion (up 294.76% YoY), and the FY2025 annual result was $50.9 billion, up 294.76% from the prior year.
• Shares Outstanding climbed to $50.9 billion in Q4 2025 per RDHL's latest filing, from $12.9 billion in the prior quarter.
• Over five years, Shares Outstanding peaked at $50.9 billion in Q4 2025 and troughed at $526.8 million in Q4 2021.
• A 5-year average of $15.7 billion and a median of $12.7 billion in 2023 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding soared 980.5% in 2023, then climbed 1.2% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $526.8 million in 2021, then surged by 123.92% to $1.2 billion in 2022, then soared by 980.5% to $12.7 billion in 2023, then gained by 1.2% to $12.9 billion in 2024, then soared by 294.76% to $50.9 billion in 2025.
• Business Quant data shows RDHL's Shares Outstanding at $50.9 billion in Q4 2025, $12.9 billion in Q4 2024, and $12.7 billion in Q4 2023.